Compare iShares MSCI Germany (DAX) (EWG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Organon & Co. Common Stock — how do they compare? iShares MSCI Germany (DAX) trades at $40.94 (market cap $1.52B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 2.4× iShares MSCI Germany (DAX)'s market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 55 Days and Organon & Co. Common Stock for 0 Days on average.
| EWG | OGN | |
|---|---|---|
Market Cap | $1.52B | $3.61B |
Volume | 368,231 | 1,808,049 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $13.81 |
52-Week Low | $38.08 | $5.70 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.20 with a modest 0.59% daily gain, though technical indicators signal a bearish trend with moving averages showing 4 buy versus 9 sell signals. The stock faces resistance at $42 with support at $41. Recent European market focus highlights resilience amid ECB rate hikes and energy price pressures affecting regional equities.
Outlook remains cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on European economic stability, but risks include prolonged inflation and energy market volatility. Stock-specific fundamentals are unavailable, requiring deeper due diligence.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
